Bio-Rad Laboratories BIO
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 81st percentile, 5-year average -10.6x
#566 of 2994 stocks by PE (1 = cheapest)
Above its usual level · 62nd percentile, 5-year average 1.2x
#1983 of 5331 stocks by PB (1 = cheapest)
Around its usual level · 58th percentile, 5-year average 3.9x
#3583 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 1.30 | – | 1.24 | 62% (pricier than usual) | #1983 of 5331 (1 = cheapest) |
| PE | 9.73 | 43.12 | -10.56 | 81% (pricier than usual) | #566 of 2994 (1 = cheapest) |
| PS | 3.80 | 3.73 | 3.93 | 58% (pricier than usual) | #3583 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on BIO.
Sign in to join the discussion.